“Project Integrum” is a unique and innovative large-scale drug development initiative initiated by Biocytogen, which is built upon the human antibody platform RenMice (RenMab, RenLite, and RenNano) and their derived 6 six major technological platforms: fully human monoclonal antibodies, bispecific antibodies, bispecific antibody-drug conjugates (ADCs), nanobodies, TCR-mimic antibodies, and GPCR antibodies.
These platforms are utilized for the development of antibody-based drugs against 1000+ targets in various forms such as monoclonal antibodies, bispecific antibodies, nanobodies, ADCs, TCR-mimic antibodies, and cell therapies, catering to the enormous global medical demand.
With the formation of a rich diversity of high-quality antibody molecule library, the program is committed to achieving the goal of new drug development through technology innovations and open and cooperative attitude with global pharmaceutical companies.
In Vivo Efficacy
Target gene knockout